Technologies

The present invention relates to a gamma camera for intracavitary use, which is widely used in the field of radio-guided surgery (intra-operative and laparoscopic and robotic-assisted) for the localisation of lymph nodes and tumours and/or other pathologies. The aim of the present invention is to make available an intraoperative tool able to overcome the drawbacks of the present known art.

Inert biomedical devices with modular load-bearing function designed with peculiar multi-domain composite microstructures. The reference compositional system is Zirconia-Alumina with a prevailing overall composition of customizable zirconia or alumina. Examples of devices are 3D structures consisting of parts with differentiated functional properties, due to different composition/microstructure/architecture, and further functionalizable ex-post to favor and improve the stabilization of the implantation by newly formed bone in superior quantity and quality.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

TNBC affects around 170,000 patients worldwide each year and accounts for 15-20% of breast cancer; compared to other types of breast cancer, TNBC is more aggressive and precocious. Its diagnosis, made difficult by the existence of subtypes with different characteristics, is fundamental to establish prognosis and personalized therapy. Nucleic acid aptamers are highly selective low-molecular-weight molecules, synthesizable at low cost and easily modifiable, capable of binding and detecting tissue markers ("aptahistochemistry”). Our team has iden

This technology is based on an algorithm able to provide the probability of being asthmatic with high accuracy. This probability is based on the evaluation of respiratory function and, specifically, of forced expiratory vital capacity in the first second (FEV₁), in resting conditions, and 20 minutes after administration of a bronchodilator drug.